ContraFect Corporation (CFRX): Price and Financial Metrics
GET POWR RATINGS... FREE!
CFRX Stock Price Chart Interactive Chart >
CFRX Price/Volume Stats
| Current price | $3.64 | 52-week high | $4.76 |
| Prev. close | $3.38 | 52-week low | $2.11 |
| Day low | $3.35 | Volume | 82,900 |
| Day high | $3.65 | Avg. volume | 86,863 |
| 50-day MA | $3.67 | Dividend yield | N/A |
| 200-day MA | $3.41 | Market Cap | 143.17M |
ContraFect Corporation (CFRX) Company Bio
ContraFect Corporation, a biotechnology company, focuses on discovering and developing therapeutic protein and antibody products for life-threatening, drug-resistant infectious diseases in the United States. The company was founded in 2008 and is based in Yonkers, New York.
Latest CFRX News From Around the Web
Below are the latest news stories about CONTRAFECT Corp that investors may wish to consider to help them evaluate CFRX as an investment opportunity.
ContraFect (CFRX) Investor Presentation - SlideshowThe following slide deck was published by ContraFect Corporation in conjunction with this event.... |
ContraFect (CFRX) Receives a Buy from Leerink PartnersLeerink Partners analyst Roanna Ruiz maintained a Buy rating on ContraFect (CFRX – Research Report) today and set a price target of $9.00. The company's shares closed last Tuesday at $3.33. According to TipRanks.com, Ruiz 's ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -34.1% and a 18.8% success rate. Ruiz covers the Healthcare sector, focusing on stocks such as Enanta Pharmaceuticals, Xeris Pharmaceuticals, and Atea Pharmaceuticals. The word on The Street in general, suggests a Strong Buy analyst consensus rating for ContraFect with a $10.25 average price target, implying a 222.3% upside from current levels. |
ContraFect to Present at the SVB Leerink 11th Annual Global Healthcare ConferenceYONKERS, N.Y., Feb. 10, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX) , a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, announces today that Roger Pomerantz, M.D., President, Chief Executive Officer and Chairman of ContraFect, will participate in a fireside chat at the SVB Leerink 11 th Annual Global Healthcare Conference, which is being held virtually from February 14–18, 2022. The fireside chat will be held on Thursday, February 17, 2022 at 10:00 AM ET. |
ContraFect Announces Award from the Cystic Fibrosis Foundation to Evaluate Exebacase as a Potential Treatment for Serious MRSA Lung Infections Associated with Cystic FibrosisYONKERS, N.Y., Jan. 06, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, today announces that it has received an additional award from the Cystic Fibrosis Foundation (CFF). This contract award will support investigation of the potent |
How Much Of ContraFect Corporation (NASDAQ:CFRX) Do Institutions Own?A look at the shareholders of ContraFect Corporation ( NASDAQ:CFRX ) can tell us which group is most powerful... |
CFRX Price Returns
| 1-mo | -2.41% |
| 3-mo | 8.98% |
| 6-mo | 3.41% |
| 1-year | -9.45% |
| 3-year | -9.70% |
| 5-year | -74.00% |
| YTD | 38.40% |
| 2021 | -47.92% |
| 2020 | -18.64% |
| 2019 | -59.43% |
| 2018 | 51.49% |
| 2017 | -42.29% |
Loading social stream, please wait...